

Teva's specialty pipeline

Phase 1	Phase 2	Phase 3	Registration
TV-46139 (abuse deterrent) <i>Pain</i>	Laquinimod <i>Multiple sclerosis (progressive forms)</i>	Laquinimod <i>Multiple sclerosis (relapsing remitting)</i>	CEP-33237 ER Hydrocodone (abuse deterrent) <i>US - Pain</i>
SD-809 <i>Tourette syndrome</i>	Laquinimod <i>Huntington disease</i>	SD-809 <i>Tardive dyskinesia</i>	Copaxone® 40mg 3w ROW <i>Multiple sclerosis</i>
SD-560 <i>Idiopathic pulmonary fibrosis</i>	Pridopidine <i>Huntington disease</i>	TV-46763 (abuse deterrent) <i>Pain</i>	Copaxone® 20mg per Day Japan <i>Multiple sclerosis</i>
Reslizumab SC <i>Asthma</i>	TV-45070 Topical <i>Neuropathic pain</i>	Fluticasone Propionate MDPI <i>Asthma</i>	SD-809 <i>Huntington Disease</i>
Fluticasone Salmeterol (MDI) EU <i>Asthma, COPD</i>	TEV-48125 (anti CGRP) <i>Chronic and episodic migraine</i>	Fluticasone Salmeterol MDPI <i>Asthma</i>	Reslizumab IV <i>Asthma</i>
TEV-46017 (tidal inhaler) <i>COPD</i>	CEP-41750 (mesenchymal precursor cell) <i>Acute myocardial infarction</i>	QVAR® (BAI) US <i>Asthma</i>	Fluticasone Salmeterol Spiromax EU <i>Asthma, COPD</i>
TEV-48107 (tidal inhaler) <i>COPD</i>	TV-1106 (Albutropin) – peds <i>Growth hormone deficiency</i>	CEP-41750 (mesenchymal precursor cell) <i>Chronic heart failure</i>	Bendamustine Rapid Infusion** <i>CLL, NHL</i>
TEV-90110 <i>HIV</i>		TV-1106 (Albutropin) – adults <i>Growth hormone deficiency</i>	
TEV-90111 <i>HIV</i>			
TEV-90112 <i>HIV</i>			
TEV-90113 <i>HIV</i>			

** Filed by Eagle Pharmaceutical, commercialized by Teva

Note: Pipeline is correct as of July 2015. Phase 1 includes also projects designated for IND filing.